![FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma](https://oncodaily.com/pub/uploads/2024/04/fda_approved.jpg)
Jun 22, 2024, 17:06
FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma
Iván R. González, Medical Oncologist at
“FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma. Thanks to the effectiveness of the KEYNOTE-868 study where the following was obtained:
dMMR cohort: SLP not reached vs. 6.5 months (HR 0.30; p<0.0001)
pMMR Cohort: SLP 11.1 months vs. 8.5 months (HR 0.60; p<0.0001)
Pembrolizumab, combined with chemotherapy, significantly improves progression-free survival in both groups.”
Source: Iván R. González/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023